There are 2+ publications for this product available. The Mouse Monoclonal anti-EPH Receptor B4 antibody is suitable to detect EPH Receptor B4 in samples from Human. It has been validated for ELISA and IHC.
EPHB4
Reactivity: Human
ELISA
Host: Mouse
Monoclonal
1D1
unconjugated
Application Notes
ELISA: 1/10000
Restrictions
For Research Use only
Format
Liquid
Buffer
Ascitic fluid containing 0.03 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C
Storage Comment
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Chrencik, Brooun, Recht, Kraus, Koolpe, Kolatkar, Bruce, Martiny-Baron, Widmer, Pasquale, Kuhn: "Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity." in: Structure (London, England : 1993), Vol. 14, Issue 2, pp. 321-30, (2006) (PubMed).
Wu, Suo, Risberg, Karlsson, Villman, Nesland: "Expression of Ephb2 and Ephb4 in breast carcinoma." in: Pathology oncology research : POR, Vol. 10, Issue 1, pp. 26-33, (2004) (PubMed).
Target
EPH Receptor B4 (EPHB4)
Alternative Name
EphB4
Background
EPH receptor B4 (EphB4), with 987-amino acid protein (about 108 kDa), belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. The Eph receptor tyrosine kinases and their ligands, the ephrins, regulate numerous biological processes in developing and adult tissues and have been implicated in cancer progression and in pathological forms of angiogenesis. EphB4 acts as a negative regulator of blood vessel branching and vascular network formation, switching the vascularization program from sprouting angiogenesis to circumferential vessel growth. EphB4 and its ligand ephrinB2 express in several kinds of tumor cells and correlate with tumorigenesis. EphB4 is thus a potential candidate as a predictor of disease outcome in several kinds of tumor and as target for novel therapy.